Guggenheim initiated coverage of Corbus Pharmaceuticals (CRBP) with a Buy rating and $45 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections
- Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone
- Corbus Pharmaceuticals announces last person enrolled in CANYON-1 trial
- Corbus Aligns With FDA on CRB-701 Registrational Path
- Corbus reports FDA alignment for CRB-701, CMO Dominic Smethurst departure